SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-20-000062
Filing Date
2020-05-15
Accepted
2020-05-15 16:11:12
Documents
14
Period of Report
2020-05-14
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K rvnc20208-k5142020annu.htm   iXBRL 8-K 47768
  Complete submission text file 0001479290-20-000062.txt   189783

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20200514.xsd EX-101.SCH 4466
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20200514_cal.xml EX-101.CAL 642
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20200514_def.xml EX-101.DEF 1492
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20200514_lab.xml EX-101.LAB 26142
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20200514_pre.xml EX-101.PRE 13598
11 EXTRACTED XBRL INSTANCE DOCUMENT rvnc20208-k5142020annu_htm.xml XML 4519
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 20885254
SIC: 2834 Pharmaceutical Preparations